Name: PH-797804
Brand: BOC Sciences
Rating: 5 (1 reviews)

IUPACName

3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxopyridin-1-yl]-N,4-dimethylbenzamide

Synonyms

PH 797804; PH797804; 3-(3-Bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide

InChI Key

KCAJXIDMCNPGHZ-UHFFFAOYSA-N

InChI

InChI=1S/C22H19BrF2N2O3/c1-12-4-5-14(21(28)26-3)9-18(12)27-13(2)8-19(20(23)22(27)29)30-11-15-6-7-16(24)10-17(15)25/h4-10H,11H2,1-3H3,(H,26,28)

SMILES

CC1=C(C=C(C=C1)C(=O)NC)N2C(=CC(=C(C2=O)Br)OCC3=C(C=C(C=C3)F)F)C

Mechanism

Target: This ligand targets p38α mitogen-activated protein kinase MAPK14 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for p38α mitogen-activated protein kinase MAPK14. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings p38α mitogen-activated protein kinase MAPK14 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

Applications

• PROTAC-Mediated Degradation Studies: PH-797804 can be used as a ligand component to build PROTAC constructs aimed at inducing ubiquitin-proteasome–dependent degradation of a chosen target protein. In research workflows, it supports systematic evaluation of ternary-complex formation, cellular target engagement, and degradation kinetics across relevant cell lines.

• Ternary Complex Optimization: Incorporating PH-797804 into PROTAC designs enables optimization of cooperative binding between the target protein and the E3 ligase. Researchers can vary linker length, attachment sites, and dosing regimens to enhance ternary complex stability, thereby improving degradation potency and selectivity while minimizing off-target proteolysis.

• Structure–Activity Relationship Mapping: PH-797804-based PROTACs can be leveraged to map structure–activity relationships by comparing analogs with different linker chemistries and stereochemical features. This approach helps identify features that govern binding geometry, ubiquitination efficiency, and degradation magnitude, supporting rational refinement of PROTAC potency.

• Mechanism of Action Profiling: PH-797804-containing PROTACs are suitable for mechanistic studies that distinguish degradation from mere inhibition. Experiments such as proteasome dependency assays, ubiquitination readouts, and time-resolved western blotting can clarify degradation pathways and determine whether PH-797804-enabled constructs drive rapid turnover of the target.

1.Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial.

MacNee W1, Allan RJ, Jones I, De Salvo MC, Tan LF. Thorax. 2013 Aug;68(8):738-45. doi: 10.1136/thoraxjnl-2012-202744. Epub 2013 Mar 28.

RATIONALE: Chronic obstructive pulmonary disease (COPD) is a common lung disease leading to progressive decline in lung function. Inhibition of release of inflammatory mediators by p38 inhibitors may be a useful treatment for chronic inflammation of the airways thought to underlie the pathogenesis of the disease.

2.Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.

Xing L1, Shieh HS, Selness SR, Devraj RV, Walker JK, Devadas B, Hope HR, Compton RP, Schindler JF, Hirsch JL, Benson AG, Kurumbail RG, Stegeman RA, Williams JM, Broadus RM, Walden Z, Monahan JB. Biochemistry. 2009 Jul 14;48(27):6402-11. doi: 10.1021/bi900655f.

PH-797804 is a diarylpyridinone inhibitor of p38alpha mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. On the basis of structural comparison with a different biaryl pyrazole template and supported by dozens of high-resolution crystal structures of p38alpha inhibitor complexes, PH-797804 is predicted to possess a high level of specificity across the broad human kinase genome. We used a structural bioinformatics approach to identify two selectivity elements encoded by the TXXXG sequence motif on the p38alpha kinase hinge: (i) Thr106 that serves as the gatekeeper to the buried hydrophobic pocket occupied by 2,4-difluorophenyl of PH-797804 and (ii) the bidentate hydrogen bonds formed by the pyridinone moiety with the kinase hinge requiring an induced 180 degrees rotation of the Met109-Gly110 peptide bond. The peptide flip occurs in p38alpha kinase due to the critical glycine residue marked by its conformational flexibility.

3.Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase.

Selness SR1, Devraj RV, Devadas B, Walker JK, Boehm TL, Durley RC, Shieh H, Xing L, Rucker PV, Jerome KD, Benson AG, Marrufo LD, Madsen HM, Hitchcock J, Owen TJ, Christie L, Promo MA, Hickory BS, Alvira E, Naing W, Blevis-Bal R, Messing D, Yang J, Mao MK, Bioorg Med Chem Lett. 2011 Jul 1;21(13):4066-71. doi: 10.1016/j.bmcl.2011.04.121. Epub 2011 May 11.

The synthesis and SAR studies of a novel N-aryl pyridinone class of p38 kinase inhibitors are described. Systematic structural modifications to the HTS lead, 5, led to the identification of (-)-4a as a clinical candidate for the treatment of inflammatory diseases. Additionally, the chiral synthesis and properties of (-)-4a are described.

4.Discovery and characterization of atropisomer PH-797804, a p38 MAP kinase inhibitor, as a clinical drug candidate.

Xing L1, Devadas B, Devraj RV, Selness SR, Shieh H, Walker JK, Mao M, Messing D, Samas B, Yang JZ, Anderson GD, Webb EG, Monahan JB. ChemMedChem. 2012 Feb 6;7(2):273-80. doi: 10.1002/cmdc.201100439. Epub 2011 Dec 15.

PH-797804 ((aS)-3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamde) is a diarylpyridinone inhibitor of p38 mitogen-activated protein (MAP) kinase derived from a racemic mixture as the more potent atropisomer (aS), first proposed by molecular modeling and subsequently confirmed by experiments. Due to steric constraints imposed by the pyridinone carbonyl group and the 6- and 6'-methyl substituents of PH-797804, rotation around the connecting bond of the pyridinone and the N-phenyl ring is restricted. Density functional theory predicts a remarkably high rotational energy barrier of >30 kcal mol(-1), corresponding to a half-life of more than one hundred years at room temperature. This gives rise to discrete conformational spaces for the N-phenylpyridinone group, and as a result, two atropic isomers that do not interconvert under ambient conditions. Molecular modeling studies predict that the two isomers should differ in their binding affinity for p38α kinase; whereas the atropic S (aS) isomer binds favorably, the opposite aR isomer incurs significant steric interference with p38α kinase.

ConcentrationVolumeMass	1 mg	5 mg	10 mg
1 mM	2.0951 mL	10.4756 mL	20.9512 mL
5 mM	0.4190 mL	2.0951 mL	4.1902 mL
10 mM	0.2095 mL	1.0476 mL	2.0951 mL
50 mM	0.0419 mL	0.2095 mL	0.4190 mL

PH-797804 is a p38 MAP kinase ligand scaffold suitable for exploratory kinase degrader design. Its brominated pyridone and difluorobenzyl elements should be preserved during linker-vector optimization.

Structure: PH-797804 is a p38 MAP kinase ligand containing a brominated 2-pyridone core, a difluorobenzyl ether substituent, and an N-methylbenzamide region. The molecule includes halogenated aryl groups, lactam/amide functionality, and a rigid heteroaryl recognition scaffold.

Reactivity: PH-797804-derived PROTAC design should preserve the bromopyridone and difluorobenzyl recognition elements. Linker installation is best explored from a solvent-exposed aryl, benzamide, or ether-associated vector in designed analogs rather than directly modifying the core lactam. Alkyl, PEG, amide, ether, or carbamate linkers may be paired with CRBN, VHL, or IAP ligands after confirming that p38 MAP kinase binding is retained.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂